Cantor Fitzgerald Reiterates Neutral Rating on Merck & Co., Inc. (MRK)

Market Context

Merck & Co., Inc. operates in the Healthcare sector. The stock currently trades at $126.78 with a market capitalization of $248.8B. The stock has gained 54.5% over the past 52 weeks.

Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Merck & Co., Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Merck & Co., Inc.

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 06, 2026	Cantor Fitzgerald	Neutral	N/A
Jun 30, 2026	Scotiabank	Sector Outperform	N/A
Jun 30, 2026	B of A Securities	Buy	N/A
Jun 24, 2026	CICC	Outperform	N/A
May 06, 2026	Citigroup	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View MRK Stock Page